KR20220132802A - Composition for preventing hair loss and improving hair growth and product comprising thereof - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for preventing hair loss and promoting hair growth, which is effective for the vast majority of hair loss patients, and a product containing the same. More specifically, an object of the present invention is to provide a pharmaceutical composition for preventing hair loss and promoting hair growth which is effective for the vast majority of hair loss patients, including finasteride, minoxidil, diuretic, magnesium hydroxide and the like.

Description

Pharmaceutical composition for preventing hair loss and promoting hair growth, and products comprising the same

The present invention relates to a pharmaceutical composition for preventing hair loss and promoting hair growth, comprising a 5α-reductase inhibitor and minoxidil, and a product comprising the same.

Hair loss refers to a state in which the proportion of hair growing in the hair follicles in the degenerative or resting phase is higher than the hair growing in the hair follicles in the growth phase during the hair follicle growth cycle, and more hairs than the normal number of hairs fall out due to various reasons.

The causes of hair loss studied so far include endocrine system abnormalities such as hormonal imbalance, excessive sebum production due to circulatory system abnormalities such as autonomic nervous system and blood circulation disorders, nutritional deficiency of hair roots, allergies, bacterial infection, genetic factors, mental stress, and atmospheric conditions. It is estimated that it is caused by environmental factors such as pollution or food and aging. Alopecia has only occurred in middle-aged people in the past, but recently, it is also frequently occurring in young people and women in their 20s and 30s.

The effects of commercially available products as hair growth promotion or hair loss prevention agents on hair include growth phase induction effect, hair growth phase extension effect, 5α-reductase inhibitory effect, blood circulation promotion effect, sterilization effect, anti-dandruff effect, moisturizing effect, antioxidant effect However, the effect of preventing hair loss and promoting hair growth in the existing formulations is not sufficient.

In addition, as surgical methods for treating hair loss, there are scalp flap surgery, hair loss site reduction, scalp plastic surgery by tissue expansion, and autologous hair transplantation, which has recently been developed. There is a disadvantage in that it is difficult to use widely because the economic and mental burden on the patient is very large.

Accordingly, there is a formulation containing minoxidil from Upzon that has been approved by the US FDA as a drug for treating and preventing alopecia, and recently, Merck Corporation inhibits the action of type 2 5 alpha-reductase (5α-reductase) to dihydrotestosterone. Propecia, the main ingredient of which inhibits the production of finasteride, has been released and used. However, in the case of minoxidil, there is a problem that side effects such as itchiness and irritation appear, and in the case of finasteride, there is a problem that it returns to its original state within 2 months if the use is stopped.

In addition, the administration of minoxidil and finasteride at the same time does not bring any significant improvement in terms of effectiveness, and yet there is no known pharmaceutical composition for hair growth that produces almost 100% of the effect and maintains the hair growth effect even if the administration is gradually reduced. It is not currently.

Korean Patent Application Laid-Open No. 2002-0005332 discloses a pharmaceutical composition in which black beans, black rice, black sesame, mung bean, perilla, seaweed and kelp are mixed in addition to minoxidil and finasteride. However, there is a need for a more innovative treatment for hair loss.

Korean Patent Publication No. 2002-0005332

It is an object of the present invention to provide a pharmaceutical composition for preventing hair loss and promoting hair growth that is effective for a large number of hair loss patients.

More specifically, an object of the present invention is to provide a pharmaceutical composition for preventing hair loss and promoting hair growth that is effective for a large number of hair loss patients, including finasteride, minoxidil, diuretics, magnesium hydroxide, and the like is to do

The object of the present invention is not limited to the objects mentioned above, and other objects not mentioned will be clearly understood from the description of the detailed description.

According to one aspect, the present invention provides 0.1 to 2 mg of 5α-reductase inhibitor (5α-reductase inhibitor) or a pharmaceutically acceptable salt thereof, 0.1 to 10 mg of minoxidil or a pharmaceutically acceptable salt thereof, 1 to 50 mg of diuretic, 10 to 1000 mg of magnesium or a pharmaceutically acceptable salt thereof, 10 to 500 mg of tocopherol or a pharmaceutically acceptable salt thereof and 500 to 2000 mg of omega 3 ( It provides a pharmaceutical composition for preventing hair loss and promoting hair growth made by mixing with omega 3).

In addition, the 5α-reductase inhibitor of the pharmaceutical composition of the present invention may be finasteride (finasteride) or dutasteride (dutasteride).

In addition, the minoxidil or a pharmaceutically acceptable salt thereof of the pharmaceutical composition of the present invention may be minoxidil sulfate.

In addition, the diuretic of the pharmaceutical composition of the present invention may be hydrochlorothiazide (hydrochlorothiazide).

In addition, the magnesium or a pharmaceutically acceptable salt thereof of the pharmaceutical composition of the present invention may be magnesium hydroxide.

In addition, the tocopherol or a pharmaceutically acceptable salt thereof of the pharmaceutical composition of the present invention may be DL-α-tocopherol acetate (DL-α-tocopherol acetate).

In addition, the omega 3 of the pharmaceutical composition of the present invention may be omega-3 acid ethyl esters 90 (omega-3 acid ethyl esters 90).

According to another aspect, there is provided a hair loss treatment method in which the pharmaceutical composition of the present invention is administered once a day for up to 6 months, twice a day for 7 months to 12 months, and once 3 days from 13 months.

According to the pharmaceutical composition of the present invention, unlike the conventional prescription that is effective only in about 70% of hair loss patients, it can exhibit almost 100% effect for hair loss patients, giving great confidence and courage to many patients suffering from hair loss. Not only that, but also the industrial and economic effects are expected to be enormous.

Figure 1 (a) is a photograph of the scalp of the hair loss patient of Example 1 before taking the pharmaceutical composition of the present invention, Figure 1 (b) is at a time point 25 weeks after taking the pharmaceutical composition of the present invention This is a photo of the scalp of the same patient.

Hereinafter, the present invention will be specifically described.

The pharmaceutical composition for preventing hair loss and promoting hair growth of the present invention has been studied to improve the effects of conventional FDA-approved drugs.

The effect of oral finasteride or minoxidil for scalp application varies greatly depending on the hair loss patient, and it was a reality that the improvement effect of hair loss was up to 70% even when the two drugs were used in combination.

Accordingly, the inventors of the present invention, while continuing intensive research to find a drug that exhibits almost 100% hair growth effect, found that the use of diuretics, magnesium preparations, tocopherol and omega 3 in addition to the above drugs significantly increases the hair growth effect. and completed the present invention.

Each drug is briefly described below.

First, there are two major 5α-reductase inhibitors used in the composition of the present invention, which are finasteride and dutasteride, respectively.

(1) finasteride

It is a drug that has the effect of inhibiting an internal enzyme called 5-α-reductase that converts testosterone into dihydrotestosterone (DHT: dihydrotestosterone) (refer to Formula 1). The dihydrotestosterone mainly acts on the hair follicles to cause hair loss, and finasteride prevents hair loss by blocking the 5-α-reductase and inhibiting the production of DHT. However, there are two types of 5-α-reductase, type 1 and type 2, of which finasteride inhibits only type 2.

(2) dutasteride

Unlike finasteride, which inhibits 5-α-reductase type 2, it is a drug that acts on both types 1 and 2 of 5-α-reductase (refer to Formula 2). It is widely known as a treatment for benign prostatic hyperplasia because it lowers the level of DHT, which also affects the prostate, by causing a rapid decrease in the concentration of DHT in the body. Although the ability to inhibit 5-α-reductase is stronger than that of finasteride, it is also a drug that has not been approved by the FDA as a hair loss drug due to the increased probability of sexual dysfunction, which is a side effect.

(3) minoxidil

Unlike drugs that inhibit DHT production and exhibit a hair growth effect, the mechanism by which minoxidil (Reference: Formula 3) promotes hair growth has not yet been precisely elucidated. However, regardless of the inhibition of male hormones, it is currently speculated that it induces hyperpolarization of cell membranes, expands blood vessels, acts as a potassium channel opener, strengthens the supply of oxygen and nutrients to the hair follicles, and reduces the resting period of the hair follicles, thereby showing a hair growth effect. have. Mainly, 3~15% of external preparations are marketed, and there are also oral preparations. Oral minoxidil is also used for the treatment of high blood pressure patients. The disadvantage of minoxidil is that it inhibits collagen synthesis, making it easier to wrinkle the skin.

(4) hydrochlorothiazide

It is a diuretic used to treat high blood pressure, congestive heart failure, edema caused by kidney or liver dysfunction, edema caused by premenstrual tension, and edema caused by drugs. Hydrochlorothiazide (Ref: Formula 4) acts on the distal tubules of the kidney and blocks the reabsorption of filtered sodium from the glomerulus, thereby increasing the excretion of sodium and water and consequently exhibits diuretic action. One of the reasons for using hydrochlorothiazide in the composition of the present invention is to alleviate the retention of salt and water, which is one of the results of the action of minoxidil.

(5) magnesium hydroxide

Magnesium Hydroxide (Reference: Chemical Formula 5) is a basic substance that acts as an antacid administered to gastric and duodenal ulcers, gastritis, and hyperacidity. In addition, magnesium itself is an important mineral necessary for our body, and it is known to help bone health by helping calcium to be transported well in the body, while also playing a role in preventing mental diseases such as anxiety, depression, and panic disorder.

(6) DL-α-tocopherol (DL-α-tocopherol)

As shown in Formula 6 below, tocopherol having a long isoprenoid side chain and a substituted aromatic ring that can penetrate the cell membrane can be divided into alpha, beta, gamma, and delta according to the functional group attached to the tocopherol, and each Tocopherol has 8 optical isomers. Most of the tocopherols used are alpha tocopherols, beta, gamma and delta tocopherols are almost excreted, and only alpha tocopherols are excreted from the liver into the blood. Tocopherol, as a biological antioxidant, serves to remove oxygen and other free radicals, and has a function of reducing cell damage by preventing the oxidation of cell membrane lipids. Since it has a structure similar to that of K, another fat-soluble vitamin in addition to its antioxidant function, it is also known that excessive intake of tocopherol acts competitively with vitamin K, thereby interfering with the anticoagulant action of vitamin K.

In addition, since adults have a very large amount of vitamin E, which is a generic term for tocopherol, a deficiency phenomenon occurs very rarely. In a person lacking vitamin E, the cell membrane of red blood cells is vulnerable to oxidative damage, and hemolytic anemia may occur.

(7) omega-3-acid ethyl ester

In the structure of the compound, fatty acids in which the position of the double bond first appears at the 3rd to the end carbon are collectively named omega-3. Omega-3 used as a drug includes the general form of omega-3-acid triglycerides ) and omega-3-acid ethyl esters purified using ethanol (refer to Chemical Formula 7). Omega-3- used in the composition of the present invention is omega-3-acid ethyl ester. Omega-3-acid ethyl ester, in the form of an oral drug, reduces triglyceride synthesis in the liver and, together with other drugs, prevents secondary occurrence after myocardial infarction. Omega-3 is commonly used as a health functional food in addition to pharmaceuticals. In this case, it is used to help improve blood triglycerides, improve blood circulation, improve memory, or improve dry eyes to help improve eye health. The omega-3 used in the composition of the present invention may be rTG omega-3, which can further promote absorption in the body in addition to the omega-3-acid ethyl ester.

As described above, the components used in the composition of the present invention have been examined in detail, but among the components used in the composition of the present invention, the 5-α-reductase inhibitor is not limited to the above finasteride and dutasteride, and Alphatra Diols (alfatradiol) and the like may also be used.

Specific examples of the present invention are described below, but the present invention is not limited to these examples.

Example

Merck's Propecia (finasteride) 1mg, Hyundai Minoxidil Tablet (Minoxidil) 5mg, Yuhan Corporation Dicrozig Tablet (hydrochlorothiazide) 25mg, Shinil M Tablet (Magnesium Hydroxide) 500mg, Shinil Oropherol Soft Capsule (DL-Tocopherol Acetate) 100mg, Ildong Pharmaceutical Omega 3 Max (omega-3-acid ethyl ester) 1200mg was mixed to prepare a pharmaceutical composition for promoting hair growth. This was administered as a pharmaceutical composition for oral administration to alopecia patients once a day for a total of 6 months or more (see Table 1).

In addition, as a comparative example, when only 1 mg of Merck's Propecia (finasteride) and 5 mg of Hyundai Minoxidil tablet (minoxidil) were administered to alopecia patients once a day for a total of 6 months or longer, as Comparative Example 1, in addition to this, DL-tocopherol acetate and omega-3-acid ethyl ester were administered to alopecia patients once a day for a total of 6 months or longer as Comparative Example 2 (see Table 1).

ingredient Example Comparative Example 1 Comparative Example 2 Finasteride 1mg 1mg 1mg minoxidil 5mg 5mg 5mg hydrochlorothiazide 25mg magnesium hydroxide 500mg DL-Tocopherol Acetate 100mg 100mg Omega-3-acid ethyl ester 1200mg 1200mg

In addition, the alopecia patient was selected according to the selection and exclusion criteria described in Table 2 below, and the same site was measured every time based on the site with the most severe hair loss. This is called a hair loss mark. In addition, the number of hairs per unit area (number of hairs/cm ² ) and hair thickness (㎛) of the area marked with hair loss were measured using a simple hand-held phototrichogram (Folliscope, Lead M Co, Seoul, Korea). As for the number of hairs per unit area, the number of terminal hairs in the unit area was calculated after photographing the area marked with hair loss using a 30x lens. The thickness of the hair was measured as the average value after measuring the thickness of 5 strands around the display area using a 200x lens.

Changes in the number of hairs (number of hairs/cm ² ) and hair thickness (㎛) specified at a certain time point after drug administration and before drug administration of the alopecia patients are shown in Table 3 below.

alopecia patient
Selection Criteria ① Male or female alopecia patients diagnosed with androgenetic alopecia aged 18-60 years
② Patients with androgenetic alopecia diagnosed as M2 or higher or C2 or higher or U1 or higher for basic type and V1 or higher or F1 or higher for basic and specific (BASP) classification
③ Patients who will not use special hair products or hair care and manipulation during the study period
④ Patients who will not receive surgical treatment for hair loss such as hair transplantation or scalp reduction during the study period
⑤ Patients who will maintain the same hairstyle during the study period
⑥ Male patient with rapid hair loss recently alopecia patient
Exclusion Criteria ① Those who have had serious acute kidney or heart disease that may affect the test results within the last 6 months
② Those with psychiatric disorders
③ Those with infectious skin disease
④ Those who have received surgical treatment for hair loss such as hair transplantation or scalp reduction in the past 5 years
⑤ Those who have used oral Finasteride or oral Dutasteride for the past 12 months
⑥ Those who have applied topical hair growth agents, wool, or hair restorers for the past 6 months
⑦ Those who are judged to have trouble applying the test substance due to severe seborrheic dermatitis, scalp psoriasis, scalp infection, etc.
⑧ Patients with other hair loss diseases such as alopecia areata, telogen alopecia, and scar alopecia in addition to androgenetic alopecia
⑨ Pregnant women or those who are highly likely to become pregnant among women with alopecia
⑩ In addition to the above, a person who is judged to be difficult to conduct the test according to the judgment of the test director

composition ratio measurement point 5 weeks 10 weeks 15 weeks 20 weeks 25 weeks Example Finasteride 1mg + Minoxidil 5mg + HCT 25mg + Mg(OH) ₂ 500mg + TA 100mg + Omega 3 1200mg One Number of hairs in the hair loss area/cm ² 8 11 15 32 38 Hair thickness at the hair loss area (㎛) 44.3 45 45.3 51.1 53.6 2 Number of hairs in the hair loss area/cm ² 7 12 12 28 31 Hair thickness at the hair loss area (㎛) 49.3 49.5 52.3 56 57 3 Number of hairs in the hair loss area/cm ² 3 3 6 19 24 Hair thickness at the hair loss area (㎛) 51.7 53.6 55.7 61.1 63.4 4 Number of hairs in the hair loss area/cm ² 33 34 34 48 55 Hair thickness at the hair loss area (㎛) 42.5 42.7 46.3 54.7 61.2 5 Number of hairs in the hair loss area/cm ² 40 43 44 58 67 Hair thickness at the hair loss area (㎛) 33.5 37.4 38 42.7 45.4 6 Number of hairs in the hair loss area/cm ² 31 32 34 48 65 Hair thickness at the hair loss area (㎛) 48.8 51.1 53.6 59.8 64.2 7 Number of hairs in the hair loss area/cm ² 35 38 47 49 53 Hair thickness at the hair loss area (㎛) 42.1 42.4 46.8 46.9 51.2 8 Number of hairs in the hair loss area/cm ² 6 6 7 15 32 Hair thickness at the hair loss area (㎛) 44.2 44.6 45.7 49 51.4 Comparative Example 1 Finasteride 1mg + Minoxidil 5mg One Number of hairs in the hair loss area/cm ² 7 8 10 12 13 Hair thickness at the hair loss area (㎛) 38.4 38.6 39.1 40.3 40.2 2 Number of hairs in the hair loss area/cm ² 8 10 11 14 16 Hair thickness at the hair loss area (㎛) 44.5 46.3 47.5 48.8 49.2 3 Number of hairs in the hair loss area/cm ² 11 13 14 17 22 Hair thickness at the hair loss area (㎛) 51.2 51.3 52.6 54 55 4 Number of hairs in the hair loss area/cm ² 35 33 34 37 39 Hair thickness at the hair loss area (㎛) 47 47.1 49.2 51.2 52 Comparative Example 2 Finasteride 1mg + Minoxidil 5mg + TA 100mg + Omega 3 1200mg One Number of hairs in the hair loss area/cm ² 10 11 13 15 19 Hair thickness at the hair loss area (㎛) 37.4 38.8 40 41.2 45.3 2 Number of hairs in the hair loss area/cm ² 21 23 24 35 36 Hair thickness at the hair loss area (㎛) 44.5 46.2 47.1 53.6 57.1 3 Number of hairs in the hair loss area/cm ² 23 24 29 31 37 Hair thickness at the hair loss area (㎛) 38.9 42.5 43.6 47.5 54.1 4 Number of hairs in the hair loss area/cm ² 31 30 28 31 33 Hair thickness at the hair loss area (㎛) 48.9 49.1 49.3 50.4 51.2

Note 1) In the table above, the hair thickness at the hair loss area means the total thickness of 1 cm ² hairs in the hair loss area divided by the number of hairs.

Note 2) Among the composition ratios in the table above, HCT represents hydrochlorothiazide, TA represents DL-α-tocopherol acetate, and omega 3 represents omega-3-acid ethyl ester.

By combining the data of Examples and Comparative Examples 1 and 2, Table 4 below summarizes the number of hair loss areas and the rate of increase in hair thickness at the hair loss area between the 5th and 25th weeks of the experiment.

composition ratio Data classification Growth rate between 5 and 25 weeks Example Finasteride 1mg + Minoxidil 5mg + HCT 25mg + Mg(OH) ₂ 500mg + TA 100mg + Omega 3 1200mg One Number of hairs in the hair loss area/cm ² 475% Hair thickness at the hair loss area (㎛) 120% 2 Number of hairs in the hair loss area/cm ² 443% Hair thickness at the hair loss area (㎛) 116% 3 Number of hairs in the hair loss area/cm ² 800% Hair thickness at the hair loss area (㎛) 123% 4 Number of hairs in the hair loss area/cm ² 167% Hair thickness at the hair loss area (㎛) 144% 5 Number of hairs in the hair loss area/cm ² 168% Hair thickness at the hair loss area (㎛) 135% 6 Number of hairs in the hair loss area/cm ² 210% Hair thickness at the hair loss area (㎛) 132% 7 Number of hairs in the hair loss area/cm ² 151% Hair thickness at the hair loss area (㎛) 122% 8 Number of hairs in the hair loss area/cm ² 533% Hair thickness at the hair loss area (㎛) 116% Comparative Example 1 Finasteride 1mg + Minoxidil 5mg One Number of hairs in the hair loss area/cm ² 186% Hair thickness at the hair loss area (㎛) 105% 2 Number of hairs in the hair loss area/cm ² 200% Hair thickness at the hair loss area (㎛) 111% 3 Number of hairs in the hair loss area/cm ² 200% Hair thickness at the hair loss area (㎛) 107% 4 Number of hairs in the hair loss area/cm ² 111% Hair thickness at the hair loss area (㎛) 110% Comparative Example 2 Finasteride 1mg + Minoxidil 5mg + TA 100mg + Omega 3 1200mg One Number of hairs in the hair loss area/cm ² 190% Hair thickness at the hair loss area (㎛) 121% 2 Number of hairs in the hair loss area/cm ² 171% Hair thickness at the hair loss area (㎛) 128% 3 Number of hairs in the hair loss area/cm ² 161% Hair thickness at the hair loss area (㎛) 139% 4 Number of hairs in the hair loss area/cm ² 106% Hair thickness at the hair loss area (㎛) 105%

As can be seen in Table 4, in Examples 1 to 8, it can be seen that the increase rate of the number of hairs in the hair loss site ranges from a minimum of 151% to a maximum of 800%, in particular Examples 1 to 3 and It can be seen that the hair number increase rate at 8 is 443% to 800%. For reference, a photograph of the scalp of the hair loss patient of Example 1 before and after taking (25 weeks elapsed time) is shown in FIG. 1 . Figure 1 (a) is a photograph before taking, Figure 1 (b) is a photograph taken at 25 weeks after taking the pharmaceutical composition of the present invention.

It can be seen that Comparative Examples 1 and 2 also exhibit a hair growth effect. In Comparative Example 1, it can be seen that the increase rate of the number of hairs in the bald area is from a minimum of 111% to a maximum of 200%, and in Comparative Example 2, the increase rate of the number of hairs in the bald area It can be seen that this is a minimum of 106% and a maximum of 190%. It can be seen that the increase in the number of hairs in Comparative Examples 1-1, 1-2 and 1-3, and Comparative Example 2-1, which is a case in which hair loss is relatively severe, is 186% to 200%. It can be seen that the composition of the present invention exhibits an excellent effect in a case in which hair loss is relatively severe, compared with the Examples of the present invention.

In addition, when comparing the hair thickness of the hair loss area, it was found that the Example increased 116% to 144%, Comparative Example 1 increased by 105% to 111%, and Comparative Example 2 increased by 105% to 139% was found to have increased. This indicates that DL-α-tocopherol acetate and omega-3-acid ethyl ester additionally added in Comparative Example 2 rather than Comparative Example 1 are effective for hair thickness. However, although it is not a big difference, it was found that the hair thickness effect was the most excellent in the case of Examples.

In addition, in the case of Comparative Examples 1 to 2, it was found that shedding phenomenon occurred at the initial stage of hair loss treatment. As can be seen in Table 3, in the case of Comparative Examples 1-4 and Comparative Examples 2-4, It can be seen that the shading phenomenon occurs. However, it can be seen that the shedding phenomenon does not appear in any of the eight cases of the embodiment.

On the other hand, a peculiar fact that can be found in the data of Examples of the composition of the present invention is that the effect appears explosively from the 20th week of treatment. This was also confirmed in the interviews with hair loss patients who participated in the experiment, and it was the point that the patients who had tried several other hair growth products set it apart from other products. That is, after 5 months of treatment, the effect of hair growth improved dramatically, and everyone was surprised, and all of them saw the effect, which eventually led to the filing of a patent application for the present invention.

In addition, after 5 to 6 months, it was further confirmed that there is no problem in maintaining the effect even if the dosage of the composition of the present invention is reduced by half or the number of dosages is changed from once a day to once every two days.

However, among the six components of the pharmaceutical composition of the present invention, minoxidil has a side effect of causing edema, and overcoming these side effects should be a task in the future, and in this invention, only considerations from the functional aspect are considered.

In addition, FDA-approved drugs currently on the market are oral administration of finasteride and scalp application of minoxidil (3%, 5%). indicates.

composition ratio measurement point 5 weeks 10 weeks 15 weeks 20 weeks 25 weeks Reference example Finasteride 1mg + minoxidil 5% applied to the hair loss area (once a day) One Number of hairs in the hair loss area/cm ² 6 6 7 7 8 Hair thickness at the hair loss area (㎛) 39.1 38.4 40.2 41.3 42 2 Number of hairs in the hair loss area/cm ² 7 4 4 6 7 Hair thickness at the hair loss area (㎛) 41.6 42.3 44.3 43.7 44.8 3 Number of hairs in the hair loss area/cm ² 7 8 6 11 15 Hair thickness at the hair loss area (㎛) 32.3 33.1 35.9 38.4 39.8 4 Number of hairs in the hair loss area/cm ² 12 11 12 14 18 Hair thickness at the hair loss area (㎛) 45.2 44.8 46.3 47.1 49

As can be seen from Table 5, it was difficult to expect a hair growth effect only by application of minoxidil, and it was found that the shedding phenomenon was also larger than that of Comparative Examples 1 and 2. Thus, it was found that the hair growth effect of the pharmaceutical composition of the present invention is significantly superior to that of the existing drug.

Claims (8)

0.1 to 2 mg of 5α-reductase inhibitor or a pharmaceutically acceptable salt thereof;
0.1 to 10 mg of minoxidil or a pharmaceutically acceptable salt thereof;
1-50 mg of diuretic;
10 to 1000 mg of magnesium or a pharmaceutically acceptable salt thereof;
10 to 500 mg of tocopherol or a pharmaceutically acceptable salt thereof; and
A pharmaceutical composition for preventing hair loss and promoting hair growth consisting of 500 to 2000 mg of omega 3 (omega 3) mixed. According to claim 1,
The 5α-reductase inhibitor is a pharmaceutical composition for preventing hair loss and promoting hair growth, characterized in that it is finasteride or dutasteride. According to claim 1,
The pharmaceutical composition for preventing hair loss and promoting hair growth, characterized in that the minoxidil or a pharmaceutically acceptable salt thereof is minoxidil sulfate. According to claim 1,
The diuretic is a pharmaceutical composition for preventing hair loss and promoting hair growth, characterized in that hydrochlorothiazide (hydrochlorothiazide). According to claim 1,
The magnesium or a pharmaceutically acceptable salt thereof is a pharmaceutical composition for preventing hair loss and promoting hair growth, characterized in that magnesium hydroxide. According to claim 1,
The tocopherol or a pharmaceutically acceptable salt thereof is DL-α-tocopherol acetate (DL-α-tocopherol acetate), a pharmaceutical composition for preventing hair loss and promoting hair growth. According to claim 1,
The omega 3 is a pharmaceutical composition for preventing hair loss and promoting hair growth, characterized in that it is omega-3-acid ethyl esters. Claims 1 to 7, characterized in that the pharmaceutical composition for preventing hair loss and promoting hair growth is administered once a day for up to 6 months, twice a day for 7 months to 12 months, and once 3 days from 13 months How to treat hair loss.

Images